Funding for this research was provided by:
National Institutes of Health (R01 GM117591, U54-CA225088)
Defense Advanced Research Projects Agency (W911NF-14-1-0397)
Received: 6 April 2021
Accepted: 24 July 2021
First Online: 6 August 2021
: All data used in this study was retrieved from public databases, and thus, it is already published and publicly available. Our research conformed to the principles of the Helsinki Declaration.
: Not applicable
: R.R. is a member of the SAB of AimedBio, consults for Arquimea Research and is founder of Genotwin. PKS is a member of the SAB or Board of Directors of Applied Biomath LLC, Glencoe Software Inc., and RareCyte Inc. and has equity in these companies; his is also on the SAB of NanoString Inc. In the last 5 years, the Sorger lab has received research funding from Novartis and Merck. Sorger declares that none of these relationships are directly or indirectly related to the content of this manuscript. The remaining authors declare that they have no competing interests.